Skip to main content

Monacum Partners acquires API Manufacturing Facility from Evotec SE

Munich, 5th November 2024

Monacum Partners, a Munich-based private equity firm, announced today the acquisition of the API manufacturing business Evotec DS GmbH in Halle/Westphalia from Evotec SE. This acquisition is in line with Monacum Partners’ strategy to invest in companies with significant value creation potential, adding a well-established Pharmaceutical Contract Development and Manufacturing Organization (CDMO) business to its portfolio.

Under the new name DAPIN GmbH (Deutsche API & Intermediates), the business that is well established in the chemical APIs and intermediates, will continue to expand its capabilities under Monacum Partners’ ownership. The entire workforce will remain part of DAPIN GmbH, and the full production capacity will be utilized to maintain its position as a reliable, innovative partner to the pharmaceutical industry. Financial terms of the transaction were not disclosed.

“We are thrilled to bring one of the leading chemical API production facilities into our portfolio. The strength of the team and the established processes at DAPIN GmbH will provide a solid foundation for future growth and innovation,” said Tobias Wilmes, Managing Partner at Monacum Partners. “We see significant potential to drive the company’s strategic vision and continue delivering top-quality solutions to our customers”.

About Monacum Partners

Monacum Partners is a Munich based private equity firm, focused on repositioning of European headquartered businesses. The core of Monacum Partners strategy, is acquiring underperforming companies with significant operational improvement potential and supporting them through proven turnaround playbooks, implemented by Monacum Partners’ experienced operational team.

About Evotec SE

Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. For additional information please go to www.evotec.com.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Monacum Partners GmbH
Ohmstraße 22 
80802 München

info@monacumpartners.com